| Patent application number | Description | Published |
|---|
| 20080226614 | Eukaryotic Based Synergistic Formulation for Gastro-Intestinal Disorders - The present invention describes a eukaryotic based synergistic formulation for gastro-intestinal disorders comprising eukaryolics and adjuncts selected from pharmaceutically and or physiologically acceptable components. The invention also describes the manner in which the eukaryolics are isolated from tropical fruits , The medium used for growing them and the method used to convert the formulation to dispensable forms. The medium comprising Glucose for carbon source, soybean casein dextrose medium (SCDM) for Nitrogen source, MgSo4, KCl, NaCl, (NH)4HPO4 and with microelements like MnSO4, FeSO4, Boric acid and Vitamins, D-Biotin and thiamine HCl ranging from 0.001% to 0.6% and designated as BBIL-SB. The formulation can be effectively used to prevent and or cure gastro intestinal disorders by administering in various forms to the mammals including human suffering there from, in a required quantity. | 09-18-2008 |
| 20080311216 | Epidermal Growth Factor Composition, A Process Therefor and Its Application - A composition for treating a wound, wherein the composition can comprise therapeutically effective amount of an epidermal growth factor and a physiologically acceptable agent, wherein the physiologically acceptable agent comprises at least one of a stabilizer, a preservative, a thickening agent, carrier/diluent, and optionally pH regulating agent and humectant. | 12-18-2008 |
| 20090220538 | VACCINE FOR STAPHYLOCOCCAL INFECTIONS - The present invention describes method of preparation and use of polypeptide vaccine formulation for prevention and control of Staphylococci mediated infections in human, bovine and other mammals, using recombinant DNA technology. | 09-03-2009 |
| 20100015123 | NOVEL THROMBOLYTIC MOLECULES AND A PROCESS THEREFOR - New thrombolytic protein molecules such as recombinant staphylokinase or streptokinase, urokinase, tissue plasminogen activator and the like, and suitable variants thereof, for targeting to brain tissue or any other tissue by either fusing to, or by synthesizing the candidate thrombolytic molecule(s) with a protein sequence comprising a strong amphipathic alpha helix containing protein transduction domain. Thrombolytic protein molecule(s) so engineered with the protein transduction domain is useful for enhanced uptake of such protein thrombolytic molecule(s) across the cell membranes and tissues including the blood brain barrier and find their use in the treatment of vascular thrombosis including cerebrovascular disorders caused by cerebral thrombosis or cerebral haemorrhage when used a as a therapeutic. The design and processes for cloning, expression, purification and protein transduction of such proteins across cell membranes. | 01-21-2010 |
| 20100068227 | Composition Useful as a Vaccine - The present invention relates to a composition comprising a viral antigen, a first protein and a second protein. Optionally, the composition also comprises three different disaccharaides, or, optionally, the composition comprises a primary sugar and at least one, preferably two secondary sugars. The present invention also relates to the use of a viral antigen, a first protein and a second protein for the manufacture of a composition, preferably a vaccine. The present invention furthermore relates to a method of treatment or prevention of virus associates diseases in humans. Moreover, the present invention relates to a method of adapting a virus to a suitable cell-line. The invention is also useful for the production of virus suspensions suitable for making stable, live/inactivated, monovalent and/or polyvalent, liquid/lyophilized rotavirus vaccine compositions for oral and/or nasal or any other suitable route of administration in human. | 03-18-2010 |
| 20100173842 | VACCINE FOR STAPHYLOCOCCAL INFECTIONS - The invention relates to a method of preparation and use of a polypeptide vaccine formulation for prevention and control of Staphylococci mediated infections in human, bovine and other mammals, using recombinant DNA technology. | 07-08-2010 |
